Alkem Laboratories Ltd

Alkem Laboratories Management Change

Alkem Laboratories CFO Nitin Agrawal resigned effective 30 September 2026 for new opportunities. He was also a Key Managerial Personnel of the company.

Alkem Laboratories Debt & Borrowing: ₹593.5 Cr

Alkem Laboratories issued a Corporate Guarantee of Euro 54.45 Million to HSBC UK Bank for a Euro 49.5 Million term loan taken by its subsidiary, Occlutech Holding.

Value

₹593.5 Cr

Alkem Laboratories Product Launch

Alkem launches NeuCeno (cenobamate), an anti-seizure medication for partial-onset seizures in adults, for the first time in India. The once-daily drug is available in six tablet strengths.

Alkem Laboratories Management Change

Alkem Laboratories has appointed Dr. Shubhadeep Sinha as a Senior Management Personnel, effective September 15, 2026. This appointment falls under standard senior management disclosures.

Alkem Laboratories Product Launch

Alkem launched Renocia Exo, a patented exosome-based hair growth serum. It expands the company's dermatology portfolio with a new follicle-support therapy.

Alkem Laboratories Annual General Meeting

Alkem Laboratories Limited concluded its 52nd Annual General Meeting on August 27, 2026. All resolutions proposed in the notice were duly approved by the members.

Alkem Laboratories Capital Structure Change

HDFC Mutual Fund disclosed an acquisition of 25,019 shares of Alkem Laboratories, increasing their aggregate holding to 5.017%. This triggers a mandatory regulatory disclosure.

Alkem Laboratories Investor Presentation: Key Takeaways

Alkem reported Q1FY27 revenue of INR 3,740cr, up 11% YoY. India sales grew 10.3%, while International jumped 16%. EBITDA margin stood at 20.5%. Net profit declined 21.7% due to taxation.

Call

Guides 12% growth

Alkem Laboratories Merger & Restructuring

Alkem Laboratories held an NCLT-convened meeting of equity shareholders to approve the Scheme of Amalgamation with Adroit Biomed Limited. The scheme received majority shareholder approval.

Alkem Laboratories Capacity Expansion: ₹75 Cr Investment

Alkem Laboratories' Board approved a new block at its Baddi manufacturing facility. The company will invest up to ₹75 Crore in this capacity expansion.

Value

₹75.00 Cr

Alkem Laboratories Results Update

Alkem Laboratories reported an 11% revenue growth to ₹3,740.2 Crore for Q1FY27. Net profit stood at ₹520 Crore despite a 21.7% year-on-year decline.

Value

₹3,740 Cr

Alkem Laboratories Q1 FY27 Results: Net Profit ₹521 Cr, Down 22.0% YoY

Alkem Laboratories Ltd reported revenue from operations of ₹3,740 Cr (+10.9% YoY) and net profit of ₹521 Cr (-22.0% YoY) for Q1 FY27.

Key figure

Net profit ₹521 Cr · -22.0% YoY

Alkem Laboratories Business Update

Alkem Laboratories announced the US FDA classified its Amaliya, Daman facility as 'Official Action Indicated'. Operations continue at the site.

Alkem Laboratories Management Change

Alkem Laboratories appointed Mr. Rajpal Singh Rana as Senior Vice President – Marketing & Sales, Acute Cluster, effective August 3, 2026.

Alkem Laboratories Other Announcement

Alkem Laboratories notified the exchange that it dispatched web-links for the FY 2025-26 Annual Report to unregistered shareholders. This filing fulfills Regulation 36(1)(b) compliance requirements.

Alkem Laboratories Business Update

Alkem Laboratories Limited has filed its Business Responsibility and Sustainability Report (BRSR) for the financial year ended 31st March, 2026.

Alkem Laboratories Annual General Meeting

Alkem Laboratories issued the notice for its 52nd Annual General Meeting, scheduled for August 27, 2026, alongside the Annual Report for FY 2025-26.

Alkem Laboratories Management Change

Dr. Jitendra Singh Huda has resigned from his position as Senior Management Personnel. The resignation is effective from July 23, 2026.

Alkem Laboratories Board Meeting Date

Alkem Laboratories will hold a board meeting on 14th August 2026 to consider and approve the standalone and consolidated unaudited financial results.

Alkem Laboratories Merger & Restructuring

Alkem Laboratories completed the acquisition of a 51-55% stake in Swiss firm Occlutech Holding AG. Occlutech now becomes a step-down subsidiary of the company.

Alkem Laboratories Merger & Restructuring Worth ₹1,100 Cr

Alkem Laboratories acquired equity shares worth Rs. 1,100 Crore in its subsidiary, Alkem Medtech, via a rights issue. The investment supports Medtech's cardiovascular and orthopedic business.

Value

₹1,100 Cr

Alkem Laboratories Annual General Meeting

Alkem Laboratories convened an NCLT-ordered shareholder meeting for August 17, 2026. Shareholders will consider the proposed scheme of amalgamation with Adroit Biomed Limited.

Alkem Laboratories Legal & Regulatory

Alkem Laboratories received favorable CIT(A) orders for assessment years 2018-2023. The ruling deletes tax disallowances totaling Rs. 660.77 Crore, providing significant regulatory relief.

Value

₹660.8 Cr

Alkem Laboratories Legal & Regulatory

Alkem Laboratories received favourable tax orders from CIT(A) for AY 2018-2023. The orders involve a tax amount of ₹60.77 Crore.

Value

₹60.77 Cr

Alkem Laboratories Merger & Restructuring

Alkem Medtech will acquire 51-55% of Occlutech Holding AG through a supplementary Share Purchase Agreement. This acquisition expands Alkem's international footprint.

Alkem Laboratories Product Launch

Alkem Laboratories launched India's first semaglutide single-shot pre-filled syringes starting at INR 350. This expansion follows their March 2026 launch of injection pens.

Alkem Laboratories Earnings Call: Key Takeaways

Alkem reported strong FY26 results with landmark INR 3,000cr+ EBITDA. Strategy focuses on chronic therapy growth in India and international expansion, particularly with the semaglutide launch.

Alkem Laboratories Other Announcement

Alkem Laboratories submitted its Annual Secretarial Compliance Report for the financial year 2025-26. The report confirms overall regulatory adherence with no major non-compliance observations.

Execution

Financial Year ended March 31, 2026

Alkem Laboratories Board Meeting Outcome

Alkem Laboratories re-appointed Ms. Madhurima Singh as Executive Director for a five-year term starting December 2026. The decision, approved during a board meeting, ensures leadership continuity.

Execution

60 months

Alkem Laboratories Results Update

Alkem Laboratories reported record FY26 EBITDA and 13.5% revenue growth to ₹14,712.3 Crore. Management cited strong domestic branded generics and international business performance.

Value

₹14,712 Cr